Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
Key facts
- Who runs it
- GC Cell Corporation
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 31 Oct 2024
- Expected to end
- Feb 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- AB-201
- Cyclophosphamide
- Fludarabine
- Record updated
- 24 January 2025
- Why it stopped
- Determined that enrollment would be limited due to the change in care setting.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- ECOG performance status 0 to 1
- Histologically confirmed HER2 expressed breast or gastric/GEJ cancer IHC ≥ 2+ within 6 months prior to study entry
- Confirmed diagnosis of an advanced/unresectable or metastatic HER2+ breast or gastric/GEJ cancer that is refractory to, or intolerable of standard treatment, or for which no standard treatment is available
- Must have received prior cancer therapy: Subjects with breast cancer must have received ≥ 3 prior systemic therapies; subjects with gastric/GEJ cancer must have received ≥ 2 prior systemic therapy(ies); subjects with IHC 3+ or IHC 2+/ISH+ cancers must have received previous treatment with a HER2-targeting therapy
Who cannot take part
- Unresolved toxicities from prior anticancer therapy
- Severe disease progression or health deterioration within 2 weeks prior to lymphodepletion regimen
- Known past or current malignancy other than inclusion diagnosis
- Known clinically significant cardiac disease
- Active central nervous system (CNS) metastases, or involvement of the CNS, unless there is a history of at least 3 months of sustained remission
- Ongoing uncontrolled systemic infections requiring antibiotic, anti-fungal, or anti-viral therapy
- History of sensitivity or intolerance to cyclophosphamide or fludarabine
- Currently Pregnant or lactating
What happens in this trial
What the trial wants to find out
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases, which are phase 1a and phase 1b. The primary objective of phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.
The 2 groups in the trial
- Phase 1a Dose EscalationTreatment being tested
* Dose Escalation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression * Interventions: * Drug: AB-201 * Drug: Cyclophosphamide * Drug: Fludarabine
Treatment: AB-201, Cyclophosphamide, and Fludarabine
- Phase 1b Dose ExpansionTreatment being tested
* Dose Confirmation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression * Interventions: * Drug: AB-201 * Drug: Cyclophosphamide * Drug: Fludarabine
Treatment: AB-201, Cyclophosphamide, and Fludarabine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open-label, Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced Human Epidermal Growth Factor Receptor 2 Positive(HER2+) Solid Tumors
- Record updated
- 24 January 2025